Listing 1 - 6 of 6 |
Sort by
|
Choose an application
Precision Medicine. --- Pharmaceutical industry. --- Precision Medicine --- Precision medicine --- Médecine de précision
Choose an application
Cardiovascular system --- Cardiovascular Diseases --- Precision Medicine. --- Diseases --- Genetics --- genetics. --- Appareil cardiovasculaire --- Médecine de précision --- Maladies --- Aspect génétique
Choose an application
precision medicine --- oncology --- clinical medicine --- personalised medicine --- individualised therapy --- Personalized medicine --- Cancer --- Oncology --- Oncology. --- Personalized medicine. --- Treatment --- Treatment. --- Individualized medicine --- Medical care --- Pharmacogenetics --- Tumors --- Cancers --- Carcinoma --- Malignancy (Cancer) --- Malignant tumors --- Therapy --- Precision medicine --- Precision medicine. --- Médecine de précision --- Cancérologie --- Traitement
Choose an application
In the framework of the ATHENA project, where CHU Liège and Janssen are collaborating, my contribution and objectives demonstrated with this thesis were to explore and summarize through descriptive statistics, clinical data of patients with multiple myeloma to allow their characterization and improve treatments pathways in a personalized approach to medicine. The project took place in a federated environment and the analytics were developed using software such as R. Finally, the relevant insights of the analyses were presented in a visual way thanks to a dashboard (developed with the RShiny software) in a federated privacy-preserving platform. Dans le cadre du projet ATHENA, pour lequel collaborent le CHU de Liège et Janssen, ma contribution et mes objectifs avec ce mémoire étaient d'explorer et de résumer par des statistiques descriptives, les données cliniques de patients atteints de myélome multiple afin de permettre leur caractérisation et une amélioration de leur parcours de soins, dans une approche personnalisée de la médecine. Le projet s’est déroulé dans un environnement fédéré et les analyses ont été développées en utilisant des logiciels tels que R. Enfin, les résultats pertinents des analyses ont été présentés via des visualisations à travers un tableau de bord, plus communément appelé dashboard (développé avec le logiciel RShiny) dans une plateforme fédérée préservant la confidentialité des données des patients.
Federated Analytics --- Federated network --- Precision medicine --- Multiple Myeloma --- Myélome multiple --- Statistiques descriptives --- Analyses de survie --- Exploration de données --- Médecine de précision --- Sciences de la santé humaine > Oncologie --- Sciences du vivant > Anatomie (cytologie, histologie, embryologie...) & physiologie --- Sciences économiques & de gestion > Stratégie & innovation --- Ingénierie, informatique & technologie > Sciences informatiques --- Sciences du vivant > Biotechnologie
Choose an application
Personalized healthcare-or what the award-winning author Donna Dickenson calls "Me Medicine"-is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before-and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology.
Sociology of health --- Professional ethics. Deontology --- biotechnologie --- bio-ethiek (medische, biomedische ethiek, bio-ethische aspecten) --- Medicine, Preventive --- Patient-centered health care --- Biotechnology --- Precision Medicine --- Public Health Practice --- Social Justice. --- Common Good --- Justice --- Obligations of Society --- Good, Common --- Justice, Social --- Medical care --- Disease prevention --- Diseases --- Prevention of disease --- Preventive medicine --- Pathology --- Preventive health services --- Preventive medicine physicians --- Public health --- bioéthique (éthique médicale, biomédicale, aspects bioéthiques) --- Moral and ethical aspects. --- ethics. --- Prevention --- Individualized Medicine --- precisiegeneeskunde --- gepersonaliseerde gezondheidszorg --- médecine de précision --- soins de santé personnalisés --- Social Justice --- ethics
Choose an application
Personalized medicine --- Drug development --- Pharmacogenetics --- Biochemical markers --- Precision Medicine. --- Biomarkers --- Drug Design. --- Clinical Laboratory Techniques --- Pharmacogenetics. --- Biochemical markers. --- Drug development. --- Personalized medicine. --- analysis. --- standards. --- Pharmacology --- Biochemical genetics --- Individualized medicine --- Medical care --- Development of drugs --- Drugs --- New drug development --- Pharmacy --- Biologic markers --- Biological markers --- Markers, Biochemical --- Biochemistry --- Indicators (Biology) --- Pharmacogenomics --- Pharmacogenomic Variants --- Drug Resistance --- Toxicology --- Precision Medicine --- Computer-Aided Drug Design --- Computerized Drug Design --- Drug Modeling --- Pharmaceutical Design --- Computer Aided Drug Design --- Computer-Aided Drug Designs --- Computerized Drug Designs --- Design, Pharmaceutical --- Drug Design, Computer-Aided --- Drug Design, Computerized --- Drug Designs --- Drug Modelings --- Pharmaceutical Designs --- P Health --- P-Health --- Personalized Medicine --- Theranostics --- Individualized Medicine --- Predictive Medicine --- Medicine, Individualized --- Medicine, Personalized --- Medicine, Precision --- Medicine, Predictive --- Theranostic --- Patient-Specific Modeling --- Genetic aspects --- Development --- Precision medicine --- Precision medicine. --- Médecine de précision --- Médicaments --- Pharmacogénétique --- Marqueurs biologiques --- Développement
Listing 1 - 6 of 6 |
Sort by
|